Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Capital Expenditures (2016 - 2025)

United Therapeutics' Capital Expenditures history spans 17 years, with the latest figure at -$231.3 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 16421.43% year-over-year to -$231.3 million; the TTM value through Dec 2025 reached $116.3 million, up 423.87%, while the annual FY2025 figure was $116.3 million, 423.87% up from the prior year.
  • Capital Expenditures for Q4 2025 was -$231.3 million at United Therapeutics, down from $281.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $281.4 million in Q3 2025 and bottomed at -$231.3 million in Q4 2025.
  • The 5-year median for Capital Expenditures is $950000.0 (2021), against an average of $19.4 million.
  • The largest annual shift saw Capital Expenditures skyrocketed 27842.86% in 2023 before it tumbled 16421.43% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at -$300000.0 in 2021, then soared by 333.33% to $700000.0 in 2022, then surged by 27842.86% to $195.6 million in 2023, then plummeted by 100.72% to -$1.4 million in 2024, then crashed by 16421.43% to -$231.3 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Capital Expenditures are -$231.3 million (Q4 2025), $281.4 million (Q3 2025), and -$8.7 million (Q2 2025).